Download Neuropathy - Pipeline Review, H2 2012 Brochure

Brochure
More information from http://www.researchandmarkets.com/reports/2298704/
Neuropathy - Pipeline Review, H2 2012
Description:
Neuropathy – Pipeline Review, H2 2012
Summary
Global Markets Direct’s, 'Neuropathy - Pipeline Review, H2 2012', provides an overview of the indication’s
therapeutic pipeline. This report provides information on the therapeutic development for Neuropathy,
complete with latest updates, and special features on late-stage and discontinued projects. It also reviews
key players involved in the therapeutic development for Neuropathy. Neuropathy - Pipeline Review, Half
Year is built using data and information sourced from Global Markets Direct’s proprietary databases,
Company/University websites, SEC filings, investor presentations and featured press releases from
company/university sites and industry-specific third party sources, put together by Global Markets Direct’s
team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of
data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Neuropathy.
- A review of the Neuropathy products under development by companies and universities/research
institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration
stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Neuropathy pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Neuropathy.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies
to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Neuropathy pipeline depth and focus of
Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the
most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that
drove them from pipeline.
Contents:
2
List of Tables 4
List of Figures 5
Introduction 6
REPORT COVERAGE 6
Neuropathy Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Neuropathy 8
Neuropathy Therapeutics under Development by Companies 10
Neuropathy Therapeutics under Investigation by Universities/Institutes 11
Late Stage Products 12
Comparative Analysis 12
Mid Clinical Stage Products 13
Comparative Analysis 13
Early Clinical Stage Products 14
Comparative Analysis 14
Discovery and Pre-Clinical Stage Products 15
Comparative Analysis 15
Neuropathy Therapeutics – Products under Development by Companies 16
Neuropathy Therapeutics – Products under Investigation by Universities/Institutes 17
Companies Involved in Neuropathy Therapeutics Development 18
Quark Pharmaceuticals, Inc. 18
Sun Pharmaceutical Industries Limited 19
NeurogesX, Inc. 20
Pharnext SAS 21
Beech Tree Labs, Inc. 22
Neuropathy – Therapeutics Assessment 23
Assessment by Monotherapy Products 23
Assessment by Combination Products 24
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 29
capsaicin - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
QPI-1007 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
minocycline - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
mexiletine hydrochloride - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
thioctic acid [JAN] - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Drug For Neuropathy - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Immunoglobulin - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
SUN-44 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Drug For Toxic Neuropathies - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
N-Acetylcysteine + Lipoic Acid + Tocopherol - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Neuropathy Therapeutics – Drug Profile Updates 41
Neuropathy Therapeutics – Discontinued Products 43
Neuropathy Therapeutics - Dormant Products 44
Neuropathy – Product Development Milestones 45
Featured News & Press Releases 45
Jun 25, 2012: Baxter Announces FDA Approval For Gammagard Liquid As Treatment For Multifocal Motor
Neuropathy 45
May 04, 2012: Pfizer Stops Phase III Trial Of Lyrica Capsules CV In Neuropathic Pain Associated With HIV
Neuropathy 46
Apr 27, 2012: Baxter Presents Efficacy And Safety Data Evaluating Gammagard Liquid For Multifocal Motor
Neuropathy At AAN Annual Meeting 46
Apr 13, 2011: Santhera To Present Catena Clinical Study Results At 2011 American Academy Of Neurology
Annual Meeting 47
Appendix 48
Methodology 48
Coverage 48
Secondary Research 48
Primary Research 48
Expert Panel Validation 48
Contact Us 49
Disclaimer 49
List of Tables
Number of Products Under Development for Neuropathy, H2 2012 8
Products under Development for Neuropathy – Comparative Analysis, H2 2012 9
Number of Products under Development by Companies, H2 2012 10
Number of Products under Investigation by Universities/Institutes, H2 2012 11
Comparative Analysis by Late Stage Development, H2 2012 12
Comparative Analysis by Mid Clinical Stage Development, H2 2012 13
Comparative Analysis by Early Clinical Stage Development, H2 2012 14
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 15
Products under Development by Companies, H2 2012 16
Products under Investigation by Universities/Institutes, H2 2012 17
Quark Pharmaceuticals, Inc., H2 2012 18
Sun Pharmaceutical Industries Limited, H2 2012 19
NeurogesX, Inc., H2 2012 20
Pharnext SAS, H2 2012 21
Beech Tree Labs, Inc., H2 2012 22
Assessment by Monotherapy Products, H2 2012 23
Assessment by Combination Products, H2 2012 24
Assessment by Stage and Route of Administration, H2 2012 26
Assessment by Stage and Molecule Type, H2 2012 28
Neuropathy Therapeutics – Drug Profile Updates 41
Neuropathy Therapeutics – Discontinued Products 43
Neuropathy Therapeutics – Dormant Products 44
List of Figures
Number of Products under Development for Neuropathy, H2 2012 8
Products under Development for Neuropathy – Comparative Analysis, H2 2012 9
Products under Development by Companies, H2 2012 10
Products under Investigation by Universities/Institutes, H2 2012 11
Late Stage Products, H2 2012 12
Mid Clinical Stage Products, H2 2012 13
Early Clinical Stage Products, H2 2012 14
Discovery and Pre-Clinical Stage Products, H2 2012 15
Assessment by Monotherapy Products, H2 2012 23
Assessment by Combination Products, H2 2012 24
Assessment by Route of Administration, H2 2012 25
Assessment by Stage and Route of Administration, H2 2012 26
Assessment by Molecule Type, H2 2012 27
Assessment by Stage and Molecule Type, H2 2012 28
Ordering:
Order Online - http://www.researchandmarkets.com/reports/2298704/
Order by Fax - using the form below
Order by Post - print the order form below and send to
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Page 1 of 2
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from
USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit
http://www.researchandmarkets.com/contact/
Order Information
Please verify that the product information is correct and select the format(s) you require.
Product Name:
Neuropathy - Pipeline Review, H2 2012
Web Address:
http://www.researchandmarkets.com/reports/2298704/
Office Code:
SCHL3FA7
Product Formats
Please select the product formats and quantity you require:
Quantity
Electronic (PDF) Single User:
USD 2000
Electronic (PDF) Site License:
USD 4000
Electronic (PDF) Enterprisewide:
USD 6000
Contact Information
Please enter all the information below in BLOCK CAPITALS
Title:
First Name:
Mr
Mrs
Dr
Miss
Last Name:
Email Address: *
Job Title:
Organisation:
Address:
City:
Postal / Zip Code:
Country:
Phone Number:
Fax Number:
* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Ms
Prof
Page 2 of 2
Payment Information
Please indicate the payment method you would like to use by selecting the appropriate box.
Pay by credit card:
You will receive an email with a link to a secure webpage to enter your
credit card details.
Pay by check:
Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.
Pay by wire transfer:
Please transfer funds to:
Account number
833 130 83
Sort code
98-53-30
Swift code
ULSBIE2D
IBAN number
IE78ULSB98533083313083
Bank Address
Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.
If you have a Marketing Code please enter it below:
Marketing Code:
Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at
http://www.researchandmarkets.com/info/terms.asp
Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World